Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Scott E. Walker"'
Autor:
Scott E. Walker, John Iazzetta, Shirley Law, Salmaan Kanji, Brigitte Bolduc, François Lamontagne, Neill K.J. Adhikari
Publikováno v:
Nutrients, Vol 11, Iss 9, p 1994 (2019)
Emerging data suggest that intravenous ascorbic acid (AA) may be beneficial in patients with sepsis. Clinicians require data on stability of diluted AA for safe administration. We evaluated the stability of AA diluted in normal saline (NS) or 5% dext
Externí odkaz:
https://doaj.org/article/595e3872b14448bd9789cb1365334dc6
Autor:
L. Lee Dupuis, Betsy Poon, Andrew Ostrenga, Scott E. Walker, Shirley Law, JoEllen Weilnau, M Petrea Cober, Pacita Sales, Karen Lingertat-Walsh
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:78-87
Background Temozolomide oral suspension is not commercially available. Objective To evaluate the stability of three temozolomide 10 mg/mL suspensions prepared in Oral Mix SF® in three container types stored at 4°C and 23°C. Methods Using commercia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c16643bc012fe247d0a4a7c9b87d94
https://doi.org/10.1177/1078155220914349
https://doi.org/10.1177/1078155220914349
Autor:
Jerome A. Leis, Andrew E. Simor, Christine Peragine, Alexander Kiss, Scott E. Walker, Sandra A N Walker
Publikováno v:
Clinical Infectious Diseases. 71:2897-2904
Background Antimicrobial resistance (AMR) constitutes an international public health threat widely believed to result from excessive antimicrobial use (AMU). Numerous authorities have recommended antimicrobial stewardship programs (ASPs) to curb the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f1c547f8bdec134a0850baea25b1a83
https://doi.org/10.1093/cid/ciz1183
https://doi.org/10.1093/cid/ciz1183
Autor:
Scott E. Walker, Jean-Marc Forest, Grégoire Leclair, Jessica MacMahon, Mihaela Friciu, Isabelle St-Jean, Anaëlle Monfort
Publikováno v:
Can J Hosp Pharm
Background: Trimethoprim (TMP) and sulfamethoxazole (SMX) are widely used, in combination, to treat or prevent various infections. Unfortunately, no liquid oral formulation is currently available in Canada for patients who are unable to swallow table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c5496d6d2912d72a5ad7b1d857f374
https://doi.org/10.4212/cjhp.v74i4.3194
https://doi.org/10.4212/cjhp.v74i4.3194
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 35:366-371
Purpose: Patients with open globe injuries routinely receive fluoroquinolone (FQ) prophylaxis to prevent bacterial infectious endophthalmitis. Owing to the rarity of this infection, there ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68e14916af8e8868eaa06e1fa5c55ed
https://doi.org/10.1089/jop.2019.0013
https://doi.org/10.1089/jop.2019.0013
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1907-1915
Purpose Use of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in patients unable to swallow capsules is hindered by the lack of a commercially available oral liquid formulation in many jurisdictions. A stable oral suspension can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb1fe2e11d6c5d702c868d13ee85bf5
https://doi.org/10.1177/1078155219828806
https://doi.org/10.1177/1078155219828806
Publikováno v:
International journal of pharmaceutical compounding. 25(2)
An oral liquid formulation of nadolol, which is required for administration to patients who cannot swallow intact tablets, is not commercially available. The objective of this study was to evaluate the stability of nadolol 10 mg/mL prepared in Oral M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::996b307d01e0d23df096113baa3b188d
https://pubmed.ncbi.nlm.nih.gov/33798116
https://pubmed.ncbi.nlm.nih.gov/33798116
Autor:
Shirley, Law, Flay, Charbonneau, John, Iazzetta, William, Perks, Nathan H, Ma, Scott E, Walker
Publikováno v:
Can J Hosp Pharm
The availability of generic versions of bortezomib raises questions about the reliability of extrapolating stability data from one brand to another.To evaluate the stability of bortezomib formulations available from Janssen, Teva Canada, Actavis Phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::48e7da5435b3e115b41a96eb87746fef
https://pubmed.ncbi.nlm.nih.gov/33487656
https://pubmed.ncbi.nlm.nih.gov/33487656
Publikováno v:
The Canadian Journal of Hospital Pharmacy. 74
Background: The availability of generic versions of bortezomib raises questions about the reliability of extrapolating stability data from one brand to another. Objective: To evaluate the stability of bortezomib formulations available from Janssen, T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5349ba2b739eeaf54678b5045395c6b
https://doi.org/10.4212/cjhp.v74i1.3041
https://doi.org/10.4212/cjhp.v74i1.3041
Autor:
Patricia Lizotte, Brigitte Bolduc, Martine Lebrasseur, Michaël Chassé, Deborah J. Cook, Nicole Marinoff, Élaine Carbonneau, Shay McGuinness, Marie-Claude Battista, Estel Deblois, John Iazzetta, Christine Drouin, Emilie P. Belley-Côté, Miranda Hunt, Francois Lamontagne, Dian Cohen, Marie-Hélène Masse, Tina Millen, Scott E. Walker, Andrew G. Day, François Lellouche, David M. Maslove, Irene Watpool, Patrick Archambault, Julie Ménard, Sheila Sprague, Salmaan Kanji, Gordon H. Guyatt, Djillali Annane, Ruxandra Pinto, Daren K. Heyland, Bram Rochwerg, Rebecca Porteous, Neill K. J. Adhikari, Frédérick D’Aragon, Yaseen M. Arabi, Rachael Parke, Bharath Kumar Tirupakuzhi Vijayaraghavan, Anitra C. Carr
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-12 (2020)
Trials
Trials, BioMed Central, 2020, 21 (1), ⟨10.1186/s13063-019-3834-1⟩
Trials
Trials, BioMed Central, 2020, 21 (1), ⟨10.1186/s13063-019-3834-1⟩
Background Sepsis is a health problem of global importance; treatments focus on controlling infection and supporting failing organs. Recent clinical research suggests that intravenous vitamin C may decrease mortality in sepsis. We have designed a ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85b8010ca921e4c400a9832991421b7a
https://doi.org/10.1186/s13063-019-3834-1
https://doi.org/10.1186/s13063-019-3834-1